Why the Nufarm (ASX:NUF) share price climbed higher today

The company's shares are jumping higher on the latest news.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Nufarm Ltd (ASX: NUF) share price climbed higher today following a positive announcement from the company during afternoon trade.

At market close, the agricultural chemicals company's shares finished up 3.33% high, trading at $4.51.

Hands grabbing for high rung on a ladder pointing to the sky

Image source: Getty Images

What did Nufarm announce?

Investors are buying up Nufarm shares in hopes that the company's latest news will see penetration into new markets.

According to its release, Nufarm advised that the United States Food and Drug Administration (FDA) has approved its Nutriterra Omega-3 Canola Oil as a new dietary ingredient.

Developed by Nuseed, a wholly-owned subsidiary of Nufarm, the Canola-based Omega-3 canola oil is the world's first plant-based source of DHA and EPA long-chain omega-3 fatty acids.

Its Omega-3 profile can be used to support human nutrition (marketed as Nutriterra) and fish feed (marketed as Aquaterra).

A human clinical trial previously conducted by Nuseed recorded significantly improved omega-3 levels leading to reduced cardiovascular and cognitive risks. The dietary supplements quickly absorbed the oil's long-chain omega-3, which were merged into blood lipids.

Nufarm also believes its Aquaterra product can reduce pressure on fisheries to catch wild-fish stocks.

The company has obtained human food and fish feed approvals in Australia, New Zealand, and Canada. Additional regulatory applications in other key markets around the world are progressing.

Management commentary

Nufarm CEO, Greg Hunt commented:

The FDA's acknowledgment along with our recently completed human clinical trial, allows us to progress our plans to expand into the human nutrition market and meet a growing demand for plant-based omega-3 essential oil options.

Mr Hunt went on to add:

With FDA recognition of Nuseed's conclusion that Nutriterra is a safe new dietary ingredient, we are well placed to secure commercial partnerships that will attract new consumers, enter into new segments and raise consumption of omega-3.

About the Nufarm share price

Over the last 12 months, Nufarm shares have gained a little over 5%, with year-to-date up around 10%. The company's share price reached a 52-week high of $5.60 in April, before treading lower.

Nufarm has a market capitalisation of roughly $1.7 billion, with approximately 379 million shares on its books.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX almost pulled off a Thursday comeback today.

Read more »

Rocket takes off from the hand of a businessman.
IPOs

What's gone wrong with the SpaceX IPO?

SpaceX rocketed on the IPO, but its flight path has since stalled.

Read more »

Businessman smiles with arms outstretched after receiving good news.
ASX Share Market News

3 ASX dividend shares that look better after CGT reforms

CGT reform puts dividend growth back in the spotlight.

Read more »

Person handing out $100 notes, symbolising ex-dividend date.
Best Shares

1 ASX dividend stock down 18% I'd buy today!

This ASX dividend stock crashed through 2022 to 2025. But it looks like it has turned a corner this year.

Read more »

A miner shakes hands with a businessman or banker inside an underground mine setting.
Broker Notes

A miner and an energy company to buy according to Macquarie

The broker is bullish on these two companies.

Read more »

A businessman holds his hand to his wide-open yawning mouth as he closes his eyes and makes a funny face while he gives a wholehearted yawn.
Broker Notes

How much could ResMed shares rise according to Morgans?

Current share price weakness could be an opportunity.

Read more »

Young successful engineer, with blueprints, notepad, and digital tablet, observing the project implementation on construction site and in mine.
Broker Notes

2 ASX mining project developers which could more than triple in value

These companies are progressing their projects well.

Read more »

A young man goes over his finances and investment portfolio at home.
Broker Notes

Buy, hold, sell: Pro Medicus, Worley, and ResMed shares

Morgans has given its view on these stocks.

Read more »